SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SYNTHETECH - NZYM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McDonald who wrote (293)8/13/1999 2:45:00 PM
From: Dan Gibbs  Read Replies (1) of 372
 
Who knows. The market has never been comfortable with the lumpiness of NZYM's earnings. With the recent plant expansions, the company is well positioned to handle any new large orders that might come. When that might happen is impossible to predict. I take comfort in the fact that there are a growing number of small molecule and peptide-based drugs in development at a number of pharmaceutical companies. This alone is producing increased revenue for NZYM. Some of these drugs will almost certainly eventually reach FDA approval. That can produce a huge increase in business for NZYM, but also, as we have seen, sometimes once a drug is marketed, the drug company finds a cheaper manufacturing process that doesn't use NZYM's products. NZYM's niche has always been suppling peptide building blocks for drugs in development, and as the number of those drugs continues to grow, so will NZYM's revenue and earnings. FDA approved drugs will be a bonus, but shouldn't be seen as necessary for the future success of this company.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News